Home > Pulmonology > ERS 2021 > ERS 2021 Highlights Podcast

ERS 2021 Highlights Podcast

Presented by
Dr Rachel Giles, Medicom
Conference
ERS 2021


In this episode, Medicom’s correspondent covers 6 presentations from the European Respiratory Society (ERS) International Congress 2021, held virtually 5-8 September 2021, The topics discussed are:

  1. How respiratory muscle training can help in COVID-19 recovery

Inspiratory muscle training (IMT) is a course of therapy that consists of breathing exercises. It is a feasible, home-based, rehabilitation tool that contributes significantly to recovery from COVID-19 with only 3 sessions per week.

  1. The lasting battle of COVID-19 long-haulers

Months after infection with SARS-CoV-2, some people are still battling fatigue. In the current study, severe fatigue was negatively correlated with disease severity. Even patients with mild symptoms showed fatigue up to 10 months after initial infection.

  1. Impact of COVID-19 on RSV dynamics in France

A delayed respiratory syncytial virus (RSV) epidemic was seen in France as a result of COVID restrictions, including social distancing. This led to raised concerns regarding the burden of RSV in the already overheated healthcare system because of the COVID-19 pandemic.

  1. Food that keeps your lungs healthy

A healthy diet in mid-childhood which includes fish, fruits, vegetables, and nuts was associated with better lung function. Aiming for a variety of foods, fewer processed foods, and more plants, should be considered as a healthy approach for children to keep their lungs happy.

  1. Biomarkers in asthma: state of the art

Biomarkers are key to understanding phenotypes and may help in distinguishing patient subgroups to guide therapeutic strategies. In the NOVELTY study, biomarkers as blood eosinophils (EOS) and fractional exhaled nitric oxide (FeNO) together with atopy history did not distinguish severe asthma from severe uncontrolled asthma.

  1. Cost-effectiveness of extending palivizumab duration

Infants at high risk of respiratory syncytial virus (RSV) only receive palivizumab during the first year of life. While children remain at risk of serious complications from RSV the subsequent year, the costs of passive vaccination with this monoclonal antibody would exceed the costs of RSV-related hospital admission.

Enjoy listening!

Copyright ©2021 Medicom Medical Publishers



Posted on